- Home
- STRO vs HOWL Comparison
STRO vs HOWL Comparison
Compare STRO & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- HOWL
- Stock Information
- Founded
- STRO 2003
- HOWL 2017
- Country
- STRO United States
- HOWL United States
- Employees
- STRO N/A
- HOWL N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- HOWL Health Care
- Exchange
- STRO Nasdaq
- HOWL Nasdaq
- Market Cap
- STRO 76.5M
- HOWL 64.5M
- IPO Year
- STRO 2018
- HOWL 2021
- Fundamental
- Price
- STRO $0.91
- HOWL $2.05
- Analyst Decision
- STRO Hold
- HOWL Strong Buy
- Analyst Count
- STRO 7
- HOWL 5
- Target Price
- STRO $1.97
- HOWL $7.20
- AVG Volume (30 Days)
- STRO 480.6K
- HOWL 959.5K
- Earning Date
- STRO 11-12-2025
- HOWL 11-06-2025
- Dividend Yield
- STRO N/A
- HOWL N/A
- EPS Growth
- STRO N/A
- HOWL N/A
- EPS
- STRO N/A
- HOWL N/A
- Revenue
- STRO $104,473,000.00
- HOWL N/A
- Revenue This Year
- STRO $65.48
- HOWL N/A
- Revenue Next Year
- STRO N/A
- HOWL N/A
- P/E Ratio
- STRO N/A
- HOWL N/A
- Revenue Growth
- STRO N/A
- HOWL N/A
- 52 Week Low
- STRO $0.52
- HOWL $0.60
- 52 Week High
- STRO $4.60
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- STRO 52.61
- HOWL 67.29
- Support Level
- STRO $0.84
- HOWL $1.78
- Resistance Level
- STRO $0.95
- HOWL $2.38
- Average True Range (ATR)
- STRO 0.06
- HOWL 0.24
- MACD
- STRO -0.00
- HOWL 0.02
- Stochastic Oscillator
- STRO 65.42
- HOWL 67.00
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.